Quintiles Transitional Holdings (Q) Shares are Up 0.18%

On a relative basis, the stock has outperformed the S&P 500 by 6.28% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.18% in the last 1 week, and is up 8.92% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Quintiles Transitional Holdings (NYSE:Q): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $77.77 and $77.49 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $78.31. The buying momentum continued till the end and the stock did not give up its gains. It closed at $77.78, notching a gain of 0.52% for the day. The total traded volume was 606,106 . The stock had closed at $77.38 on the previous day.

The stock has recorded a 20-day Moving Average of 4.81% and the 50-Day Moving Average is 12.51%. Quintiles Transnational Holdings Inc. is up 17.92% in the last 3-month period. Year-to-Date the stock performance stands at 13.28%.

Quintiles Transitional Holdings (Q) : 10 Wall Street analysts covering Quintiles Transitional Holdings (Q) believe that the average level the stock could reach for the short term is $80.35. The maximum price target given is $87 and the minimum target for short term is around $71, hence the standard deviation is calculated at $5.06.


Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *